Artificial neural networks for anticoagulant management - Think again!

Israel Medical Association Journal

Volumn 6, Issue 12, 2004, Pages 770-771

  Ellis, Martin H ^a,b  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Neural network; Oral anticoagulants; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; WARFARIN; XIMELAGATRAN;

ARTIFICIAL NEURAL NETWORK; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HEART ATRIUM FIBRILLATION; HUMAN; INFORMATION PROCESSING; INTERNATIONAL STANDARD UNIT; LIVER DYSFUNCTION; LUNG EMBOLISM; PRIMARY MEDICAL CARE; RECURRENCE RISK; RISK ASSESSMENT; RISK REDUCTION; VENOUS THROMBOEMBOLISM;

ALGORITHMS; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMPUTER-ASSISTED; HUMANS; INTERNATIONAL NORMALIZED RATIO; NEURAL NETWORKS (COMPUTER); WARFARIN;

EID: 10644249060     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (8)

1. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists. Chest 2004;126:204-33S.
2. Hulen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin or both after myocardial infarction. N Engl J Med 2002;347:969-74.
3. Gadisseur AP, Breukink-Engbers WG, van der Meer FJ, et al. Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial. Arch Intern Med 2003;163: 2639-46.
4. Solomon I, Maharshak N, Chechik G, et al. Applying an artificial neural network to warfarin maintenance dose prediction. IMAJ 2004;6:732-5.
5. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003;349:1703-12.
6. Schulman S, Wahlander K, Lundstrom T, et al. Secondary prevention of venous thromboembolism with the direct oral thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713-21.
7. Olsson SB; Executive Steering Committee SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation (SPORTIF III): a randomized controlled trial. Lancet 2003;362:789-97.
8. http://www.astrazeneca.com/pressrelease/3538.aspx Accession date: 14 November 2004.